Form 4: NewAmsterdam Pharma Director and 10% Owner Boosts Stake with Recent Share Purchases

A recent SEC Form 4 filing reveals that James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., has increased his indirect beneficial ownership through significant share acquisitions in late June 2025.

Summary

• James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V. (NAMS), reported recent purchases of ordinary shares.
• On June 24, 2025, 2,520 ordinary shares were purchased at a weighted average price of $18.4343 per share, with prices ranging from $18.305 to $18.63.
• On June 25, 2025, an additional 1,260 ordinary shares were purchased at a weighted average price of $18.2632 per share, with prices ranging from $18.10 to $18.3795.
• These purchases were made indirectly through Frazier Life Sciences X, L.P.
• Following these transactions, Frazier Life Sciences X, L.P. beneficially owns 3,026,133 ordinary shares.
• The reporting person also indirectly beneficially owns 3,801,000 ordinary shares through Frazier Lifesciences Sponsor LLC.
• The total indirect beneficial ownership by James N. Topper, through these associated entities, is 6,827,133 ordinary shares.
• An incremental purchase of 200 shares on March 26, 2025, was inadvertently omitted from a previous Form 4 filed on March 28, 2025, and is now included in the reported total.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's future. The minor reporting omission does not significantly detract from the overall positive signal.

Positives

• A director and 10% owner, James N. Topper, increased his indirect beneficial ownership in NewAmsterdam Pharma Co N.V. through recent share purchases, signaling confidence in the company's future prospects.
• The total indirect beneficial ownership by Mr. Topper, through associated entities, now stands at 6,827,133 ordinary shares, representing a substantial stake.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This SEC Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. Insider buying can be interpreted by the market as a signal of confidence from those with intimate knowledge of the company's operations and prospects, potentially influencing investor sentiment within the pharmaceutical industry.

Related Party Transactions

• The reported share purchases were made by James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., through entities (Frazier Life Sciences X, L.P. and Frazier Lifesciences Sponsor LLC) where he is a managing member, constituting related party transactions as per SEC regulations.

Stakeholder Impact

• Shareholders: The insider buying by a director and 10% owner may be perceived as a positive signal, potentially increasing investor confidence and demand for the company's stock.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, SEC Form 4, Insider Trading, Share Purchase, Director Ownership, Beneficial Ownership, Frazier Life Sciences, Equity Acquisition